n INTRODUCTION F ibromyalgia (FM) is a controversial musculoskeletal pain disorder estimated to affect from 200 to 400 million people worldwide (1) . As defined by the American College of Rheumatology, it is a condition of chronic (≥3 months) widespread pain, with pain perceived on palpation of at least 11 out of 18 tender point sites throughout the body (2) . In addition to pain and tenderness, patients with FM also report secondary but invalidating symptoms, including sleep disruption, fatigue, depression, anxiety, memory and concentration problems, headaches, numbness/tingling, and other symptoms (3) . Therefore, new criteria focusing on the dysfunctional disorders associated with widespread pain have been proposed (4) . FM may cause functional disability and have a significantly negative effect on quality of life (5) . The prevalence of FM increases with age and it is especially more frequent at or near menopause (6) . In the last few years sexual dysfunction has also been ranked in the context of the disorders more frequently complained of by FM patients and, to support this, an abundance of scientific papers have been published addressing and investigating the problem (7) . Whether or not they are pathophysiologically connected to FM, the fact remains that FM patients are unequivocally more prone to develop sexual dysfunction compared to healthy controls. The leading causes for the greater incidence of sexual problems include contact-avoidance behavior due to tenderness, depression, fatigue and the effect of medications, but a history of sexual abuse, frequently reported by women affected by FM, may also contribute. Understanding the association between sexual dysfunction and FM is of importance for the development of prevention and treatment strategies. The aim of this review was, therefore, to describe the recent literature concerning sexual dysfunction in FM patients. We shall attempt to describe what is currently known about the association between FM and sexual dysfunction in women. Attention will be directed towards possible summary The aim of this review was to describe the recent literature concerning sexual dysfunction in fibromyalgic patients. To this end, we used the common online databases PubMed, MEDLINE and EMBASE (up to June 2012) and searched for the key words fibromyalgia (FM) and sexual dysfunction. All the studies examined underlined that FM is strictly associated with sexual dysfunction in women. The major findings observed were related to a decreased sexual desire and arousal, decreased experience of orgasm, and in some studies an increase in genital pain. The psychological aspects, together with the stress related to the constant presence of chronic widespread pain, fatigue and sleep disturbances, are certainly a major factor that adversely affects the sexuality of the patient with FM. Moreover, the drugs most commonly used in these cases may interfere negatively on the sexuality and sexual function of these patients. Therefore, the therapeutic intervention should be targeted and the side effects should be weighed up against the positive effects. It is of the utmost importance to recognise the problem of sexuality and sexual dysfunction in a more complex form of its expression and undertake a multidisciplinary therapeutic intervention to improve the quality of FM patients' life.
REVIEW mechanisms of such association, through a careful analysis of the instruments used, as well as the burden of psychiatric comorbidity. Finally, the changes in the various phases of the sexual cycle and the impact of sexual dysfunction on quality of life will be investigated.
n METHODS
For this review article, we searched the common online databases PubMed, MED-LINE and EMBASE (up to June 2012) using the key words fibromyalgia and sexual dysfunction and reviewed all the relevant articles in English (35 articles were identified). Moreover, we consulted an expert in sexology to evaluate the methodological approach and the choice of sexual evaluation tools.
n RESULTS
In the last few years, numerous studies concerning the association between FM and sexual dysfunction have been published. In Table I we reported the most common tools used to investigate the FM sexual impairment. In Table II The main problem with this work was the small sample size and the differences in age between the FM patients and the control group. In the study by Tikiz et al. (9) , 40 female FM patients were studied using the Female Sexual Function Index (FSFI) (10) . An important aspect of this work was the presence of mood impairment evaluation; in fact, 27 of these females suffered from depression. The main result of this study was that the reduction of FSFI was significantly decreased in the FM and FM plus (12) linked the tender point counts to muscular tenderness, which is negatively correlated with the various parameters of sexual function. However, this work has some limitations: there were differences between FM patients and controls in the level of employment, level of education and in the percentage of immigrants, which might be confounding factors on the various parameters of sexual function. In a recent work published by Yilmaz et al. (17) , the authors investigated the relationship between clinical parameters of FM and sexuality. In particular, the authors studied the FSFI, tender point count, BDI-
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Fibromyalgia and sexual problems II, Fibromyalgia Impact Questionnaire (FIQ), and Visual Analog Scale (VAS) of 126 females with FM and 132 healthy controls. They found that the FM patients had higher BDI-II scores and a lower frequency of sexual intercourse than the control subjects. Moreover, the mean FSFI scores (total and all domains) were significantly lower in FM patients than the controls. In light of this data, they suggested that FM had negative effects on sexual function, and a decrease in sexual activities was aggravated by depression, as suggested by the correlation with BDI-II. All sub-items of the FSFI were still lower in patients with fibromyalgia and depression compared to patients with fibromyalgia alone, except for the aspect of lubrication. Pain during intercourse was statistically higher in FM patients with depression. However, Yilmaz et al. (17), did not detect a reduction in the FSFI score in relation to pain.
n DISCUSSION Sexual dysfunction is common, affecting about 45% of women at least once during their lifetime (18) . In an Italian study, performed using the FSFI, the percentage of women with a score under the mean was 24.4% (19) . The most common risk related to the selfadministration of questionnaires assessing sexual trends is that the answers given may be not completely truthful because of poor social acceptability. This drawback is mitigated by the fact that the questionnaires are administered anonymously. Disorders in sexual behavior were observed more frequently in women with FM compared to healthy controls, as evidenced by several authors. Several studies report a rate of sexual dysfunction in patients with chronic pain, and since FM is characterized by chronic widespread pain we expect the same relationship. In most studies, the pain is only moderately correlated with sexual dysfunction, and in certain subgroups of patients it is not associated with it (11) or it plays a weak predictive role. Tikiz et al. (9) reported that only widespread pain was associated with sexual dysfunction in patients with FM and that the coexistence of depression is not an additional factor. On the other hand, Orellana et al. (15) reported that even if the pain of FM patients is higher, it seemed related to depression levels. The VAS pain may be directly correlated with local pain -e.g., vulvodynia, as has been reported in 21% of patients, and interstitial cystitis and burning pain during urination, as reported in 21.7% of FM patients -and it appears to significantly interfere with the psychological aspects of sexuality, as demonstrated by the decrease of sexual desire. Indeed, several authors have confirmed that the reduction in desire, probably the most common sexual problem in FM, can be identified with the difficulty of having positive feelings (20) . In all the studies, the patients rated low on the satisfaction index. This is an important observation of the discomfort of FM patients within the sexual relationship and suggests the need for strategies and therapeutic interventions, including a cognitivebehavioral therapy with the sexual partner. In addition, some psychological aspects associated with pain, such as depression, feelings of catastrophization, fear leading (Table  III) . The causes of FM are unknown, but physical and psychological trauma seem to be important. A history of sexual abuse is frequently related to FM, with direct effects on sexuality (22) . The genital response involves both sympathetic and parasympathetic components of the nervous system and both central and peripheral components. Perturbed activation of the sympathetic nervous system has been found in FM patients. Unlü et al. (23) found altered autonomic functions in FM patients that were not correlated with sexual dysfunction unlike depression and anxiety. Genetic factors are also important, resulting in an increased susceptibility to stressors (24) . Mood disorders, especially major depression and anxiety, play an important role in FM. Nonetheless, it is difficult to assess the individual weight of these factors. FM is a non-homogeneous syndrome and in many studies depression and mental distress appear related to sexual dysfunction. These observations seem to indicate that sexual dysfunction in FM is related to a psychological more than to a physiological disorder. Moreover, the drugs most commonly used to reduce the pain in these patients (e.g., selective serotonin reuptake inhibitors, serotonin and noradrenalin reuptake inhibitors and muscle relaxants) may negatively interfere on sexuality and sexual function. However, the burden of mood disorders and the influence of drug therapies are important, especially the influence of the latter on sexual function has not yet been evaluated. Therefore, the therapeutic intervention should be targeted and side effects should be weighed up against positive effects, for example by using the lowest effective dosage to reduce pain. It is of the utmost importance to recognise the problem of sexuality and sexual dysfunction in a more complex form of its expression and undertake a multidisciplinary therapeutic intervention to improve the quality of FM patients' life. Sexuality is such a fundamental aspect of life since it is related to sexual drive and the reproductive function, and it is also an important domain in the quality of life because it is related to pleasure. Further studies are needed to explain the individual weight of the plethora of FM symptoms on sexuality. A final question is to check whether sexual dysfunction is one of the causes of FM syndrome.
